SUPN EBITDA Growth
Supernus Pharmaceuticals Inc · EBITDA Growth
SUPN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-109.55%period ending
SUPN TTM EBITDA YoY % (7.27% → -109.55%)
Year-over-year change
High-resolution chart · PNG
SUPN ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -109.5541% | |
| -69.0133% | |
| -70.2254% | |
| -52.5701% | |
| 51.2003% | |
| 121.4118% | |
| 84.0287% | |
| 14.5519% | |
| -5.5251% | |
| -48.5012% | |
| -41.285% | |
| 7.294% | |
| -13.8557% | |
| 1.9847% | |
| 18.703% | |
| -27.1228% | |
| -27.0006% | |
| -27.3416% | |
| -38.6382% | |
| -23.0373% | |
| -1.6166% | |
| 8.631% | |
| 18.8139% | |
| 12.6436% | |
| 6.3121% | |
| 10.8061% | |
| 7.0674% | |
| 26.2821% | |
| 32.5773% | |
| 33.2257% | |
| 53.7126% | |
| 64.7079% | |
| 61.9008% | |
| 83.1849% | |
| 90.1812% | |
| 85.4139% | |
| 152.208% | |
| 175.9372% | |
| 160.136% | |
| 152.0247% | |
| 148.0176% | |
| 86.2074% | |
| 513.5284% | |
| 187.176% | |
| 131.1349% | |
| 118.3582% | |
| 92.9791% | |
| 71.5023% | |
| 37.4517% | |
| -38.6863% | |
| -80.3662% | |
| -56.2709% | |
| -46.1647% | |
| -12.8819% | |
| 11.2494% | |
| -5.9014% | |
| 7.2654% |